Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2121-2127

  Eiseman, Julie L ^a,b   Guo, Jianxia ^a   Ramanathan, Ramesh K ^a,b   Belani, Chandra P ^a,b   Solit, David B ^c   Scher, Howard I ^c   Ivy, S Percy ^d   Zuhowski, Eleanor G ^a   Egorin, Merrill J ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; BIOLOGICAL MARKER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; SOMATOMEDIN BINDING PROTEIN 2;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; LACTAMS, MACROCYCLIC; MALE; MICE; NEOPLASMS; RECEPTOR, ERBB-2; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247499347     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2286     Document Type: Article

References (47)

1. Yakar S, LeRoith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 2005;16:407-20.
2. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
3. Kibbey MM, Jameson MJ, Eaton EM, Rosenzweig SA. Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to insulin-like growth factor-1 binding. Mol Pharmacol 2006;69:833-45.
4. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18:801-31.
5. Ranke MB, Maier KP, Schweizer R, et al. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res 2003;60:174-80.
6. Lee DY, Kim SJ, Lee YC. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999;14:401-4.
7. Elatiq F, Garrouste F, RemacleBonnet M, Sastre B, Pommier G. Alterations in serum levels of insulin-like growth factors and insulin-like growth factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994;57:491-7.
8. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-5.
9. Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994;78:271-6.
10. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998;83:1713-20.
11. Fukuda I, Hizuka N, Takano K, Asakawa-Yasumoto K, Shizume K, Demura H. Characterization of insulin-like growth factor-II (IGF-II) and IGF binding-proteins in patients with non-islet-cell tumor hypoglycemia. Endocr J 1993;40:111-9.
12. Muller HL, Oh Y Lehrnbecher T, Blum WF, Rosenfeld RG. Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 1994;79:428-34.
13. Mohnike KL, Kluba U, Mittler U, Aumann V, Vorwerk P, Blum WF. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr 1996;155:81-6.
14. Riikonen R, Vettenranta K, Riikonen P, Turpeinen U, Saarinen-Pihkala UM. Cerebrospinal fluid insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein (IGFBP-2) in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;43:110-4.
15. Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003;30:38-48.
16. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
17. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
18. RoJS, el Naggar A, Ro JY et al. c-erbB-2amplification in node-negative human breast cancer. Cancer Res 1989;49:6941-4.
19. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990;50:6701-7.
20. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
21. Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-7.
22. Junker K, Stachetzki U, Rademacher D, et al. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer 2005;48:59-67.
23. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. Her-2/neu expression-a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
24. Yoshida K, Tsuda T, Matsumura T, et al. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch 1989;57:285-90.
25. Hou L, Shi D, Tu SM, Zhang HZ, Hung MC, Ling D. Oral cancer progression and c-erbB-2/neu protooncogene expression. Cancer Lett 1992;65:215-20.
26. Xia W, Lau YK, Zhang HZ, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997;3:3-9.
27. Ross JS, Sheehan C, Hayner-Buchan AM, et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 1997;28:827-33.
28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
29. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266:1716-20.
30. Leitzel K, Teramoto Y, Sampson E, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992;10:1436-43.
31. Ouyang X, Gulliford T, Doherty A, Huang GC, Epstein RJ. Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state- specific antibodies. Lancet 1999;353:1591-2.
32. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99.
33. Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol 2006;(172):259-77.
34. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005;146:769-80.
35. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-emethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91.
36. Solit DB, Egorin M, Kopil C, et al. Phasel pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17- demethoxygeldanamycin). J Clin Oncol 2005;23:204S.
37. Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetics and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in pediatric patients with recurrent or refractory solid tumors: a Pediatric Oncology Experimental Therapuetics Consortium (POETIC) Study. Clin Cancer Res. In press 2007.
38. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in (17-AAG) in patients with advanced cancer. Clin Cancer Res. In press 2007.
39. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
40. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
41. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
42. Zhang H, Chung D, Yang YC, et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006;5:1256-64.
43. Neidel J. Changes in systemic levels of insulin-like growth factors and their binding proteins in patients with rheumatoid arthritis. Clin Exp Rheumatol 2001;19:81-4.
44. Clemmons DR, Snyder DK, Busby WH, Jr. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 1991;73:727-33.
45. Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR. Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 1993;77:1294-9.
46. Young SC, Miles MV, Clemmons DR. Determination of the pharmacokinetic profiles of insulin-like growth factor binding proteins-1 and -2 in rats. Endocrinology 1992;131:1867-73.
47. Ramanathan RK, Egorin MJ, Eiseman JL, et al. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldamamycin (17-AAG, NSC-330507), administered on a twice-a-week schedule in adult patients with refractory advanced cancers. Clin Cancer Res. In press 2007.